Introduction
============

Thyroid carcinoma is the most common endocrine tumor and the most common tumor site in women aged 10 to 29 years. The incidence increases with age reaching a peak in the 60 to 69 age group ([@r1]). During the last few decades, the incidence of thyroid carcinoma has increased in Croatia, mostly due to the rise in the incidence of papillary thyroid carcinoma (PTC) ([@r2]), the most common type, comprising almost 90% of all thyroid cancer cases. Papillary TC is a relatively indolent, slow growing malignancy with an excellent overall prognosis. It typically remains limited to thyroid tissue or presents with metastases in regional lymph nodes. Distant metastases are rare, typically in the lungs and bones as the most common metastatic sites ([@r3]). Unusual sites of distant PTC metastases are extremely rare. Brain, liver, skin, kidney, pancreas, and adrenal gland PTC metastases have been sporadically reported in the literature ([@r4]). Due to the almost anecdotal occurrence of PTC distant metastases in unexpected sites, there is a realistic possibility of diagnostic oversight and undercalling. It is important to emphasize the crucial role of radioiodine diagnostics with whole body iodine-131 scintigraphy (I-131 whole body scan, WBS), which is based on active tumor I-131 accumulation, conditioned by the presence of NaI symporter (NIS) in tumor cells. Furthermore, evaluation with I-131 single-photon emission computed tomography/computed tomography (SPECT/CT) imaging enables precise localization, and diagnostic specificity including exclusion of false-positive results ([@r5]). In high-risk patients with suspected non-iodine avid metastases, additional F-18-fluorodeoxyglucose (FDG)-positron emission tomography (PET)/CT imaging should be advocated.

Case Report
===========

An 86-year-old female patient was admitted to the Sestre milosrdnice University Hospital Center due to vertigo, followed by nausea, vomiting and headache. Computed tomography of the brain was unremarkable. However, due to a 15 kg unintentional weight loss during the past year, further clinical workup including diagnostic imaging was performed. Cervical ultrasonography revealed nodules in both thyroid lobes and a suspicious 3 cm lymph node in region IV in the right side of the neck. Fine-needle aspiration biopsy identified PTC in the right thyroid lobe (Bethesda VI) and lymph node metastasis in region IV in the right side of the neck ([@r6]). At the time of diagnosis, the patient was euthyroid. Total thyroidectomy with bilateral paratracheal (region VI) and right selective II-V neck dissection was performed. Final histopathologic findings were consistent with classic PTC American Joint Committee on Cancer (AJCC) stage T2N1bMx, including tumor nodule measuring 3.7x2.5x2.2 cm in size without extracapsular extension, one positive lymph node in the paratracheal right neck region VI and two positive lymph nodes in the dissected region IV of the right side of the neck (infiltrated with atypical epithelial cells of light cores with intranuclear inclusions and overlapping). A follicular adenoma of the left thyroid lobe, 1.8x0.5 cm in size was also described. Dissected right neck regions II and III were histologically free of papillary TC. Postoperative oncologic examination detected high serum thyroglobulin (Tg) of more than 5000 µg/L with elevated Tg antibody titers (638.8 kIU/L; reference value \<115 kIU/L). Postoperative cervical ultrasonography was unremarkable, after which iodine-131 WBS was performed. Besides the expected smaller iodine-131 accumulation in the thyroid bed region, there was intense large focal I-131 accumulation in the upper left quadrant of the abdomen. Therefore, additional I-131 SPECT/CT of the thorax and abdomen was performed, which demonstrated avid I-131 accumulation measuring 8x6 cm in size located in the region of the left adrenal gland, highly indicative of iodine-131 avid PTC metastasis ([Fig. 1](#f1){ref-type="fig"}). In addition, ultrasound examination of the abdominal region was performed showing a solid mass measuring 76x76x59 mm, located between the spleen and the left kidney ([Fig. 2](#f2){ref-type="fig"}). Based on the above-mentioned findings, due to the age and poor overall condition including multiple comorbidities, the patient was treated with a 5809 MBq (157 mCi) dose of iodine-131. Therapy was well tolerated and subsequently, the patient was started on suppressive L-T4 therapy. After radioiodine therapy, contrast enhanced arterial phase multi-slice computed tomography (MSCT) of the thoracic and abdominal region demonstrated an expansile left adrenal gland mass sized 7.8 cm in diameter with inhomogeneous contrast opacification, including a central low attenuation area of necrosis ([Fig. 3](#f3){ref-type="fig"}). The patient's clinical condition improved significantly after radioiodine treatment. At first follow up with 131 WBS and I-131 abdominal SPET/CT, there was no interval growth of the left adrenal metastasis and no additional foci of abnormal radiotracer uptake to suggest disease progression. Further treatment options will be considered, including surgery or additional iodine-131 therapy.

![SPECT/CT with I-131 of the thoracic and abdominal region demonstrates focal intense I-131 accumulation between the spleen and left kidney in the region of the left adrenal gland.](acc-57-372-f1){#f1}

![Abdominal ultrasound performed one month after total thyroidectomy. Dimensions of the morphologically altered left adrenal gland were 76x76x59 mm.](acc-57-372-f2){#f2}

![Contrast enhanced arterial phase MSCT of the abdominal region demonstrates soft tissue mass in the left adrenal gland accompanied by radioiodine accumulation on I-131 SPECT/CT.](acc-57-372-f3){#f3}

Discussion
==========

Despite the characteristic features of PTC as an indolent and prognostically extremely favorable neoplasm, it is important to emphasize the possibility of rare and unexpected metastases at unusual sites. According to the available data, a total of nine cases of PTC metastases in the adrenal gland have been described in the literature ([@r7]), highlighting the importance and uniqueness of the case presented. In 2001, the first known case was reported in the literature as unilateral PTC metastasis in the adrenal gland ([@r8]). In 2013, for the first time bilateral adrenal PTC metastases were described ([@r9]). In our case, a radioiodine avid left adrenal gland metastasis was suspected on iodine 131 WBS and confirmed by additional I-131 SPECT/CT imaging. Besides thyroid tissue and differentiated thyroid carcinoma, NIS is also physiologically expressed in the stomach, salivary glands and lactating breast tissue. Additional tissues such as the heart, thymus, pancreas, lungs and even adrenal glands may express NIS occasionally ([@r10]). Therefore, the possibility of a false-positive finding should be excluded ([@r11]). However, high serum Tg level in conjunction with focal, intense unilateral I-131 accumulation in the projection of the left adrenal gland and visible anatomical structural changes including abnormal parenchymal enhancement of the left adrenal gland on arterial phase contrast-enhanced MSCT further supported the diagnosis of PTC metastasis. Despite the tendency of loco-regional lymphatic dissemination of PTC, the highlighted finding of a distant metastasis in the adrenal gland stresses the importance of greater attention in the search for distant metastases. This case report complements rare examples of unusual metastases of PTC. Although these metastases are extremely rare, the possibility of their occurrence should be taken in consideration in the appropriate clinical setting.
